An assessment of zonisamide as an anti-epileptic drug

Bibliography

• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (ECLAT IV). Epilepsy Res. (1999) 34:1–41.
   PubMed Web of Science ®Google Scholar
• ••Source of information about drugs in development forepilepsy.
   Google Scholar
• ROGAWSKI MA, LE DQ, UYAKUL D et al: Anticonvulsant efficacy of ADCI (5-aminocarbony1-10,11 -dihydro-5H-dibenzo [a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia (1995) 36:566–571.
   PubMed Web of Science ®Google Scholar
• SIGEL E, BAUR R, NETZER R et al: The antiepileptic drug AWD 1 31-13 8 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. NeuroscL Lett. (1998) 245:85–88.
   PubMed Web of Science ®Google Scholar
• KOZAK A, DOLINA S, KAMBURG S et al.: DP-VPA, a novelprodrug of VPA has enhanced protective effect in genetically epilepsy-prone mice. Soc. NeuroscL Abstr. (1997) 23 (part 2):2163.
   Google Scholar
• MONAGHAN EP, NAVALTA LA, SHUM L et al.: Initialhuman experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia (1997) 38:1026–1031.
   PubMed Web of Science ®Google Scholar
• JONES FA, DAVIES JA: The anticonvulsant effects of theenantiomers of losigamone. Br. J Pharmacol. (1999) 128:1223–1228.
   PubMed Web of Science ®Google Scholar
• BIBER A, DIENEL A: Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. (1996) 34:6–11.
   PubMed Web of Science ®Google Scholar
• BRYANS JS, WUSTROW DJ: 3-substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. (1999) 19:149–177.
   PubMed Web of Science ®Google Scholar
• DAVIES JA: Remacemide hydrochloride: a novel antiepileptic agent. Gen. Pharmacol. (1997) 28:499–502.
   PubMedGoogle Scholar
• RUNDFELDT C: The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. j Pharmacol. (1997) 336:243–249.
   PubMed Web of Science ®Google Scholar
• BLOTNIK S, BERGMAN F, BIALER M: The disposition of valproyl glycinamide and valproyl glycine in rats. Pharmacol. Res. (1997) 14:873–878.
   Web of Science ®Google Scholar
• MAURIZIS JC, MADELMONT JC, RAPP M et al. : Disposition and metabolism of 2,6-dimethylbenzamide n-(5-methyl-3-isoxazoly1) (D2916) in male and female rats. Drug Metab. Dispos. (1997) 25:33–39.
   PubMed Web of Science ®Google Scholar
• JAIN KK: An assessment of rufinamide as an antiepi-leptic in comparison with other drugs in clinical development. Exp. Opin. Invest. Drugs (2000) 9: 829–840.
   PubMed Web of Science ®Google Scholar
• WALKER MC, PATSALOS PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol. Ther. (1995) 67:351–384.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Neuroprotection. Jain PharmaBiotech, Basel,Switzerland (2000).
   Google Scholar
• •Role of anti-epileptics drugs as neuroprotectives is described.
   Google Scholar
• ELAN PHARMA: Zonegran (zonisamide): product monograph. San Francisco, California, USA (2000).
   Google Scholar
• NAGATOMI A, MISHIMA M, TSUZUKI 0 et al.: Utility of a rectal suppository containing the antiepileptic drug zonisamide. Biol. Pharm. Bull. (1997) 20 (8):892–896.
   Google Scholar
• KITO M, MAEHARA M, WATANABE K: Mechanisms of T-type calcium channel blockade by zonisamide. Seizure (1996) 5:115–119.
   PubMed Web of Science ®Google Scholar
• OKADA M, KAWATA Y, MIZUNO K et al.: Interactionbetween Ca2+, K+, carbamazepine and zonisamide on hippocampal ex tracellular glutamate monitored with a microdialysis electrode. Br. J. Pharmacol. (1998) 124:1277–1285.
   PubMed Web of Science ®Google Scholar
• MORI A, NODA Y, PACKER L: The anticonvulsantzonisamide scavenges free radicals. Epilepsy Res. (1998) 30:153–158.
   PubMed Web of Science ®Google Scholar
• MASUDA Y, KARASAWA T, SHIRAISHI Y et al.:3-sulfamoylmethy1-1,2-benzisoxazole, a new type of anticonvulsant drug - pharmacological profile. Arzneimittelforschung (1980) 30:477-483. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• ITO T, HORI M, MASUDA Y et al: 3-sulfamoylmethyl-1,2-benzisox azole, anew type of anticonvulsant drug - electro encephalographic profile. Arzneimittelfor-schung (1980) 30:603–609.
   PubMed Web of Science ®Google Scholar
• WADA Y, HASEGAWA H, OKUDA H et al.: An ticonvulsant effects of zonisamide and phenytoin on seizure activity of the feline visual cortex. Brain Dev. (1990) 12:206–210.
   PubMed Web of Science ®Google Scholar
• SHIMIZU M, UNO H, ITO T et al.: Research and develop-ment of zonisamide, a new type of antiepileptic drug. Yakugaku Zasshi (1996) 116:533–547.
   PubMed Web of Science ®Google Scholar
• TAKANO K, TANAKA T, FUJITA T et al: Zonisamide: electrophysiological and metabolic changes in kainic acid-induced limbic seizures in rats. Epilepsia (1995) 36:644–648.
   PubMed Web of Science ®Google Scholar
• MIMAKI T, SUZUKI Y, TAGAWA T et al.: Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med. J. Osaka Univ. (1990) 39:13–17.
   PubMedGoogle Scholar
• OKADA M, HIRANO T, KAWATA Y et al.: Biphasic effects of zonisamide on sero ton ergic system in rat hippocampus. Epilepsy Res. (1999) 34:187–197.
   PubMed Web of Science ®Google Scholar
• OKADA M, KANEKO S, HIRANO T et al.: Effects ofzonisamide on dopaminergic system. Epilepsy Res. (1995) 22:193–205.
   PubMed Web of Science ®Google Scholar
• HAYAKAWA T, HIGUCHI Y, NIGAMI H et al.: Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur. Pharmacol. (1994) 257:131–136.
   PubMed Web of Science ®Google Scholar
• MINATO H, KIKUTA C, FUJITANI B et al.: Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia (1997) 38 :975–980.
   PubMed Web of Science ®Google Scholar
• OWEN AJ, IJAZ S, MIYASHITA H et al.: Zonisamide as aneuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioural study. Brain Res. (1997) 770:115–122.
   PubMed Web of Science ®Google Scholar
• LEPPIK, SHAH J, SHELLENBERGER K et al.: Zonsiamidepharmacokinetics: direct relationship between oral dose and blood levels. Epilepsia (1999) 40 (Suppl. 2):286 (Abstract).
   Google Scholar
• MIMAKI T: Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther. Drug Monit. (1998) 20:593–597.
   PubMed Web of Science ®Google Scholar
• ••A good review of clinical pharmacology.
   Google Scholar
• KOCHAK GM, PAGE JG, BUCHANAN RA et al.: Steady-state pharmacokinetics of zonisamide, an antiepi-leptic agent for treatment of refractory complex partial seizures. J Clin. Pharmacol. (1998) 38:166–171.
   PubMed Web of Science ®Google Scholar
• PERUCCA E, BIALER M: The clinical pharmacokineticsof the newer antiepilep tic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. (1996) 31:29–46.
   PubMed Web of Science ®Google Scholar
• NAKASA H, NAKAMURA H, ONO S et al.: Prediction ofdrug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur. J. Clin. Pharmacol (1998) 54:177–183.
   PubMed Web of Science ®Google Scholar
• IEIRI I, MORIOKA T, KIM S et al.: Pharmacokinetic studyof zonisamide in patients undergoing brain surgery. J Pharm. Pharmacol. (1996) 48:1270–1275.
   PubMed Web of Science ®Google Scholar
• SHINODA M, AKITA M, HASEGAWA M et al.: The necessity of adjusting the dosage of zonisamide when coadministered with other anti-epileptic drugs. Biol. Pharm. Bull. (1996) 19:1090–1092.
   PubMed Web of Science ®Google Scholar
• WILBUR K, ENSOM MHH: Pharmacokinetic drug interactions between oral contraceptives and second-generation an ticonvulsan ts. Clin. Pharmacokinet. (2000) 38:355–365.
   PubMed Web of Science ®Google Scholar
• SUZUKI N, SEKI T, YAMAWAKI H et al.: Therapy ofpediatric epilepsy with AD-810 (zonisamide). Shonika Rinsho (1987) 40:3147–3152.
   Google Scholar
• TAGAWA T, MIMAKI T, SHUTO H et al.: Treatment ofpediatric epilepsies with zonisamide (AD-810) - efficacy and blood concentration. Shonika Shinryo (1988) 51:539–543.
   Google Scholar
• HOSODA N, MIURA H, TAKANASHI S et al.: Once dailydose of zonisamide monotherapy in the control of partial seizures in children with cryptogenic localization-related epilepsies: clinical effects and their pharmacological basis. Jpn. j Psychiat. Neurol (1994) 48:335–337.
   Google Scholar
• ITO T, YAMAGUCHI T, MIYAZAKI H et al.: Pharmacoki-netic studies of AD-810, a new antiepileptic compound. Phase I trials. Arzneimittelforschung (1982) 32:1581–1586.
   PubMed Web of Science ®Google Scholar
• WILENSKY AJ, FRIEL PN, OJEMANN LM et al.: Zonisamidein epilepsy: a pilot study. Epilepsia (1985) 26:212–220.
   PubMed Web of Science ®Google Scholar
• SACKELLARES JC, DONOFRIO PD, WAGNER JG et al.: Pilotstudy of zonisamide (1,2 -benzisoxazole-3 - methanesulfonamide) in patients with refractory partial seizures. Epilepsia (1985) 26:206–211.
   PubMed Web of Science ®Google Scholar
• FUKUSHIMA K, YAGI K, SEINO Metal.: A clinical Phase IIstudy of a new antiepileptic drug, zonisamide on the refractory epilepsy in childhood. Shonika Rinsho (1987) 40:3389–3397.
   Google Scholar
• LEPPIK IE, WILLMORE LJ, HOMAN RW et al.: Efficacy andsafety of zonisamide: results of a multicenter study. Epilepsy Res. (1993) 14:165–173.
   PubMed Web of Science ®Google Scholar
• SCHMIDT D, JACOB R, LOISEAU P et al.: Zonisamide foradd-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. (1993) 15:67–73.
   PubMed Web of Science ®Google Scholar
• OGUNI H, IINUMA K, SEKI T et al.: Open clinical Phase IIItrial of a new antiepileptic drug zonisamide for childhood epilepsy. Jpn. J. Pediatrics (1988) 41:439–450.
   Google Scholar
• ONO T, YAGI K, SEINO M: Clinical efficacy and safety ofa new antiepileptic drug, zonisamide. A multi-institutional Phase III study. Seishin Igaku (1988) 30:471-482. Exp. Opin. Pharmacother. (2000) 1(6)
   Google Scholar
• LEPPIK I, SEINO M, YAGI K et al.: International evalua-tion of zonisamide efficacy. Neurology (1998) 50:A101 (Abstract).
   Google Scholar
• CHADWICK DW, MARSON AG: Zonisamide for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. (2000) 2:CD001416.
   Google Scholar
• YAGI K, PRIVITERA MD: Efficacy of zonisamidemonotherapy. Neurology (2000) 54 (Suppl. 3):P03.099 (Abstract).
   Google Scholar
• KAWAWAKI H, KURIMASA H, TOMIWA K et al.: Efficacyof zonisamide in West syndrome. Epilepsia (1999) 40 (Suppl. 2):68 (Abstract).
   Google Scholar
• SUZUKI Y, NAGAI T, ONO J et al.: Zonisamidemonotherapy in newly diagnosed infantile spasms. Epilepsia (1997) 38:1035–1038.
   PubMed Web of Science ®Google Scholar
• YANAI S, HANAI T, NARAZAKI 0: Treatment of infantilespasms with zonisamide. Brain Dev. (1999) 21:157–161.
   PubMed Web of Science ®Google Scholar
• WALLACE SJ: Myoclonus and epilepsy in childhood: areview of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. (1998) 29:147–154.
   PubMed Web of Science ®Google Scholar
• KYLLERMAN M, BEN-MENACHEM E: Zonisamide for progressive myoclonus epilepsy: long-term observa-tions in seven patients. Epilepsy Res. (1998) 29:109–114.
   PubMed Web of Science ®Google Scholar
• KANBA S, YAGI G, KAMIJIMA K et al.: The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog. Neuropsychopharmacol. Biol. Psychiatry (1994) 18:707–715.
   PubMed Web of Science ®Google Scholar
• PETERS DH, SORKIN EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy. Drugs (1993) 45:760–787.
   Google Scholar
• SHIMIZU T, YAMASHITA Y, SATOI M et al.: Heat stroke-like episode in a child caused by zonisamide. Brain Dev. (1997) 19:366–368.
   PubMed Web of Science ®Google Scholar
• WATANABE K, OKUMURA A, HAYAKAWA F et al.: Oligohidrosis caused by zonisamide. No To Hattatsu (1996) 28:44–47.
   PubMedGoogle Scholar
• MIYAMOTO T, KOHSAKA M, KOYAMA T: Psychotic episodes during zonisamide treatment. Seizure (2000) 9:65–70.
   PubMed Web of Science ®Google Scholar
• KUMAGAI N, SEKI T, YAMAWAKI H et al.: Monotherapy for childhood epilepsies with zonisamide. Jpn. Psychiatry Neurol (1991) 45:357–359.
   PubMedGoogle Scholar
• SHELLENBERGER K, BECK K: Safety of zonasimide in Japanese children. Epilepsia (1999) 40 (Suppl. 7):94 (Abstract).
   Google Scholar